Combined immunotherapy—a new standard in metastatic melanoma? (original) (raw)

Immunotherapy

Nature Reviews Clinical Oncology volume 12, pages 439–440 (2015)Cite this article

Subjects

The efficacy of immunotherapy in metastatic melanoma is established, with anti-CTLA-4 and anti-PD-1 antibody-based therapies providing unexpectedly high responses and prolonged survival. The combination of nivolumab and ipilimumab is now poised to become the new standard of care, based on a 61% response rate in a recent randomized extended phase I/II trial, confirmed by phase III data presented at ASCO 2015.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$189.00 per year

only $15.75 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
    Article CAS Google Scholar
  2. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
    Article CAS Google Scholar
  3. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
    Article CAS Google Scholar
  4. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. https://dx.doi.org/10.1056/NEJMoa1503093.
  5. Das, R. et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194, 950–959 (2015).
    Article CAS Google Scholar
  6. Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017 (2015).
    Article Google Scholar
  7. Chapman, P. B., D'Angelo, S. P. & Wolchok, J. D. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N. Engl. J. Med. 372, 2073–2074 (2015).
    Article Google Scholar
  8. Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. https://dx.doi.org/10.1200/JCO.2014.59.4358.
  9. Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231 (2013).
    Article CAS Google Scholar
  10. Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. https://dx.doi.org/10.1056/NEJMoa1504030.

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University Hospital of Schleswig-Holstein, Campus Kiel, Schittenhelmstrasse 7, Kiel, 24105, Germany
    Axel Hauschild
  2. Division of Dermatooncology, Department of Dermatology, University Medical Center, Liebermeisterstrasse 25, Tuebingen, 72074, Germany
    Claus Garbe

Authors

  1. Axel Hauschild
  2. Claus Garbe

Corresponding author

Correspondence toAxel Hauschild.

Ethics declarations

Competing interests

A.H. has consulted and receives honoraria for Amgen, BMS, Celgene, Merck Serono, MDS/Merck, Novartis, OncoSec and Roche Pharma. C.G. receives personal fees from Amgen and Novartis, and grants and personal fees from BMS, GSK, Merck, and Roche.

Rights and permissions

About this article

Cite this article

Hauschild, A., Garbe, C. Combined immunotherapy—a new standard in metastatic melanoma?.Nat Rev Clin Oncol 12, 439–440 (2015). https://doi.org/10.1038/nrclinonc.2015.118

Download citation

This article is cited by